

Pendred Syndrome (PDS) and DFNB4 Panel

Genes Tested

<i>SLC26A4</i>	<i>FOXI1</i>	<i>KCNJ10</i>
----------------	--------------	---------------

Disorder: Approximately one-third of all children with sensorineural hearing loss have an abnormality in their temporal bones. Variants in the *SLC26A4* gene, which encodes for the pendrin protein, are identified in approximately 25-50% of children with temporal bone abnormalities and/or enlarged vestibular aqueducts.

Biallelic variants in *SLC26A4* result in one of two phenotypes: Pendred syndrome (hearing loss in association with cochlear abnormalities, enlarged vestibular aqueducts and euthyroid goiter) or DFNB4 (hearing loss and enlarged vestibular aqueducts with or without cochlear defects). Two variants are identified in 80-90% of patients with a family history of PDS, while only a single variant is identified in approximately 30% of patients with no family history of PDS. Digenic inheritance is postulated in these patients.

Heterozygous variants in two other genes, *FOXI1* and *KCNJ10*, have been reported in association with DFNB4 in a few individuals in which only a single *SLC26A4* variant was identified, thus supporting digenic inheritance as a rare cause of this condition. Of note, biallelic inheritance of two variants in *KCNJ10* causes SeSAME/EAST syndrome which is characterized by seizures, sensorineural deafness, ataxia, intellectual disability, and electrolyte imbalance.

Indications: Hearing loss of unknown etiology in association with enlargement of the ventricular aqueducts with or without a cochlear defect.

Specimen: At least 3 mLs whole blood in a lavender top (EDTA) tube or at least 2 mLs of saliva in an Oragene saliva collection kit. To request saliva kits, please call (513) 636-4474. Label each tube with patient's name, birth date, and date of collection.


Testing Methodology: This test is performed by enrichment of the coding exons, flanking intronic and un-translated regions (5' and 3') of the genes specified above using oligonucleotide probe hybridization followed by next-generation sequencing with > 50 fold coverage at every target base. All pathogenic and novel variants, as well as variants of unknown (indeterminate) significance, as determined bioinformatically, are confirmed by Sanger sequencing. If the Pendred Syndrome Panel test result is normal, reanalysis of the remaining genes on the **OtoSeq[®] Hearing Loss Panel** may be requested. Alternately, you may opt to order the **OtoSeq[®] Hearing Loss Panel**, which detects variants in these genes as well as 20 other genes which cause hearing loss, in lieu of the Pendred Syndrome Panel.

Test Sensitivity: Next-generation sequencing detects >90% of the reported variants in the *SLC26A4* gene. The variant detection rates in *KCNJ10* and *FOXI1* are not known. Large multiexon deletions have been reported in patients with Pendred syndrome, but are rare. Variants in *SLC26A4* account for approximately 8% of congenital sensorineural hearing loss overall and for approximately 25% of congenital hearing loss associated with temporal bone abnormalities.



Human Genetics

Laboratory of Genetics and Genomics
CLIA#: 36D0656333
Phone: (513) 636-4474
Fax: (513) 636-4373
Email: LabGeneticCounselors@cchmc.org
www.cchmc.org/hearing-loss



Variants in the *FOXI1* and *KCNJ10* genes are identified in less than 1% of patients with PDS/DFNB4.

The sensitivity of next-generation sequencing is over 99% for the detection of nucleotide base changes and small deletions and insertions (<10 bases) in the regions analyzed. Larger deletions, insertions and other complex genetic events are not identified using this test methodology. Rare primer site variants may lead to erroneous results.

Note: Single gene sequencing is available for all genes in the panel. Deletion/duplication analysis is available for all genes on the panel.

Turn-Around Time:

- 56 days for NGS of the panel
- Up to 42 days for analysis of any gene on the panel by Sanger sequencing
- Additional 42 days for reanalysis of remaining genes on the **OtoSeq® Hearing Loss Panel** (if requested).

Cost: Please call 1-866-450-4198 for current pricing, insurance precertification, or with any billing questions.

CPT Codes:

- | | |
|--|-------|
| • Pendred Syndrome Panel by NGS: | 81406 |
| • Single gene sequencing of <i>KCNJ10</i> | 81404 |
| • Single gene sequencing of <i>SLC26A4</i> | 81406 |
| • Single gene sequencing of <i>FOXI1</i> | 81479 |
| • OtoSeq® reanalysis (if requested) | 81479 |


Results: Each test report includes a detailed interpretation of the genetic findings, the clinical significance of the result, and specific recommendations for clinical management and additional testing, if warranted. Results will be reported to the referring physician or health care provider as specified on the test requisition form.

Shipping Instructions

Please enclose a completed **test requisition, audiogram and MRI/CT report, if available** with the sample. **All information must be completed before the sample can be processed.** Place samples in Styrofoam mailer and ship at room temperature by overnight Federal Express to arrive Monday through Friday.

Ship to:

Cytogenetics and Molecular Genetics Laboratories
3333 Burnet Avenue NRB 1042
Cincinnati, OH 45229
513-636-4474



References:

Alasti, F., G. Van Camp, et al. (1993). *Pendred Syndrome/DFNB4*. *GeneReviews*. R. A. Pagon, T. D. Bird, C. R. Dolan, K. Stephens and M. P. Adam. Seattle (WA).

Azaiez, H., T. Yang, et al. (2007). "Genotype-phenotype correlations for SLC26A4-related deafness." *Hum Genet* 122(5): 451-457.

Bizhanova, A. and P. Kopp (2010). "Genetics and phenomics of Pendred syndrome." *Mol Cell Endocrinol* 322(1-2): 83-90.

Coyle, B., W. Reardon, et al. (1998). "Molecular analysis of the PDS gene in Pendred syndrome." *Hum Mol Genet* 7(7): 1105-1112.

Dossena, S., A. Bizhanova, et al. (2011). "Identification of allelic variants of pendrin (SLC26A4) with loss and gain of function." *Cell Physiol Biochem* 28(3): 467-476.

Dossena, S., C. Nofziger, et al. (2011). "Molecular and functional characterization of human pendrin and its allelic variants." *Cell Physiol Biochem* 28(3): 451-466.

Ito, T., B. Y. Choi, et al. (2011). "SLC26A4 genotypes and phenotypes associated with enlargement of the vestibular aqueduct." *Cell Physiol Biochem* 28(3): 545-552.

Madden, C., M. Halsted, et al. (2007). "The influence of mutations in the SLC26A4 gene on the temporal bone in a population with enlarged vestibular aqueduct." *Arch Otolaryngol Head Neck Surg* 133(2): 162-168.

Pryor, S. P., A. C. Madeo, et al. (2005). "SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and nonsyndromic EVA are distinct clinical and genetic entities." *J Med Genet* 42(2): 159-165.

Yang, T., H. Vidarsson, et al. (2007). "Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4)." *Am J Hum Genet* 80(6): 1055-1063.

Yang, T., J. G. Gurrola, 2nd, et al. (2009). "Mutations of KCNJ10 together with mutations of SLC26A4 cause digenic nonsyndromic hearing loss associated with enlarged vestibular aqueduct syndrome." *Am J Hum Genet* 84(5): 651-657.

Additional information and test requisitions are available at: www.cchmc.org/hearing-loss